Enabling Faster, Better Decisions In Early Stage Development Of Microbial Based Biotherapeutics

More than half of the 150+ biopharmaceuticals developed and approved for human use through 2009 were manufactured via microbial fermentation in bacteria or yeast. Although the next decade saw a shift towards the use of mammalian cell culture systems for expression of antibodies and complex proteins that require posttranslational modifications, microbial fermentation has experienced a renaissance in recent years, particularly in the area of next-generation therapies such as antibody and small peptide fragments.

Steve Loftus, PhD, Microbial Business Steering Group Lead at FUJIFILM Diosynth Biotechnologies, describes the benefits of microbial fermentation for biologics production, and the recent improvements introduced to the Paveway microbial expression platform.